Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-07

Clinical Trial Update: Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on dose-response profile of A-101 in seborrheic keratosis with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • A-101

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Seborrheic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2018-12-07